Literature DB >> 16022715

Actively regulating bioengineered tissue and organ formation.

D J Mooney1, T Boontheekul, R Chen, K Leach.   

Abstract

OBJECTIVES: Describe current and future approaches to tissue engineering, specifically in the area of bone regeneration. These approaches will allow one to actively regulate the cellular populations participating in this process.
DESIGN: Many approaches to actively regulate cellular phenotype are under exploration, and these typically exploit known signal transduction pathways via presentation of specific receptor-binding ligands, and may also deliver mechanical information via the physical bridge formed by the receptor-ligand interactions. Cellular gene expression may also be directly modulated utilizing gene therapy approaches to control tissue regeneration.
CONCLUSIONS: Significant progress has been made to date in bone regeneration using inductive molecules and transplanted cells, and FDA approved therapies have resulted. While approaches to date have focused on delivery of single stimuli (e.g. one growth factor), future efforts will likely attempt to more closely mimic developmental processes by the delivery of multiple inputs to the cells in spatially and temporally regulated fashions.

Mesh:

Substances:

Year:  2005        PMID: 16022715     DOI: 10.1111/j.1601-6343.2005.00327.x

Source DB:  PubMed          Journal:  Orthod Craniofac Res        ISSN: 1601-6335            Impact factor:   1.826


  2 in total

1.  VEGF internalization is not required for VEGFR-2 phosphorylation in bioengineered surfaces with covalently linked VEGF.

Authors:  Sean M Anderson; Bhupinder Shergill; Zachary T Barry; Eleana Manousiouthakis; Tom T Chen; Elliot Botvinick; Manu O Platt; M Luisa Iruela-Arispe; Tatiana Segura
Journal:  Integr Biol (Camb)       Date:  2011-08-08       Impact factor: 2.192

2.  A fibrin glue composition as carrier for nucleic acid vectors.

Authors:  Ulrike Schillinger; Gabriele Wexel; Christian Hacker; Martin Kullmer; Christian Koch; Michael Gerg; Stephan Vogt; Peter Ueblacker; Thomas Tischer; Daniel Hensler; Jonas Wilisch; Joachim Aigner; Axel Walch; Axel Stemberger; Christian Plank
Journal:  Pharm Res       Date:  2008-09-10       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.